Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Immatics Biotechnologies GmbH
DescriptionVaccine containing 11 different human leukocyte antigen (HLA)-restricted tumor-associated peptides (TUMAPs)
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationBrain cancer
Indication DetailsTreat glioblastoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today